Wells Fargo Raises MannKind Target to $11 on Pediatric Afrezza Approval
The firm lifted its price target citing expanded Afrezza use in pediatric diabetes patients after FDA approval. Wells Fargo increased its price target for MannKind Corporation (NASDAQ:MNKD) to $11 from $10, maintaining an Overweight rating. The adjustment follows the FDA’s